Morgans assesses momentum continues to build with record cash receipts and growing annual recurring revenue (ARR), after Volpara Health Technologies posted its first quarter cashflow report.
The broker highlights the focus on risk assessment and genetics has been enhanced with the recent CRA Health acquisition and collaboration with Invitae Corporation.
Morgans makes no changes to forecasts and maintains its $1.87 target price and Add rating.
Sector: Health Care Equipment & Services.
Target price is $1.87.Current Price is $1.14. Difference: $0.73 - (brackets indicate current price is over target). If VHT meets the Morgans target it will return approximately 39% (excluding dividends, fees and charges - negative figures indicate an expected loss).
© 2021 Acquisdata Pty Ltd., source FN Arena